A randomised placebo controlled crossover trial to evaluate the effects of different doses of taurocholic acid in an enema formulation on gastrointestinal hormone secretion and appetite in healthy humans for the future design of treatments for Type 2 diabetes mellitus and obesity
Royal Adelaide Hospital
12 participants
Mar 2, 2011
Interventional
Conditions
Summary
The study aims to establish whether taurocholic acid, administered as an enema, can stimulate secretion of the gut peptides GLP-1, PYY, and oxyntomodulin, and suppress subsequent appetite and food intake. This information could be useful in designing treatments for type 2 diabetes and obesity.
Eligibility
Inclusion Criteria1
- Healthy subjects; Body mass index (BMI) 19 - 30 kg/m2; Haemoglobin > 135 g/L
Exclusion Criteria1
- Medications affecting gut function; Alcohol intake >20g daily or cigarette smoking; Significant gastrointestinal disease or surgery; Impaired liver or renal function; Blood donation within 3 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Each healthy volunteers will undergo three treatments (2 with different doses of taurocholic acid 1500mg and 3500mg and one with control), in double-blind, randomised fashion, separated by 3 - 7 days. On each day the test material will be administered as an enema, and each session will last 210 min.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611000071921